Chemotherapy of metastatic hepatoid adenocarcinoma: Literature review and two case reports with cisplatin etoposide.

Hepatoid adenocarcinoma (HAC) is a rare and aggressive cancer subtype with a poor prognosis under metastatic conditions. Currently, there is no specific chemotherapy treatment protocol for advanced stages of the disease. This review evaluates two cases of HAC of gastric cardia with synchronous liver metastasis, which were successfully treated by chemotherapy with cisplatin (25 mg/m2 each day) (day 1 to day 3) and etoposide (100 mg/m2) (day 1 to day 3), every three weeks. A structured literary evaluation and reviewed pertinent articles are additionally presented to analyse the different approaches for the treatment of metastatic HAC (mHAC). The two described case reports demonstrated good partial responses to treatment and one of the two patients exhibited a good prognosis after a 9-year follow-up. A total of 20 case reports concerning the use of chemotherapy in mHAC were presented in the literature, 11 of which were regarding gastric HACs. The two aforementioned cases result in a total of 22 reports, 11 of which exhibited objective responses to chemotherapy, 8 patients demonstrated a partial response and 3 a complete response. The cisplatin-based regimen concerned 55% (12/22) patients and enabled 9 (75%) to exhibit a partial or complete response. A total of three patients exhibited a good prognosis in the long-term follow-up, all of them treated with a cisplatin-based regimen. It was demonstrated that the usual digestive regimens were not efficient in the treatment of HAC. In the absence of prospective trials, it may be hypothesized that cisplatin-based chemotherapy may be the most efficient first-line treatment in mHAC, with a 75% patient response, in accordance with the literature and follow-up cases.

Introduction

Hepatoid adenocarcinoma (HAC) represents approximately 0.2 to 0.8% of diagnosed gastric cancer (1). Ishikura et al defined HAC as extrahepatic tumor with hepatocyte differentiation and potentially increased α-fetoprotein (AFP) secretion (2). HAC diagnosis is mainly histological and is characterized by large and polygonal hepatocyte-like cells with intense eosinophil cytoplasm and big central nucleus. HAC is mainly located in oesophagus and stomach, however other sites were also described (3). According to a Chinese analysis, which includes a total of 180 gastric HACs from 62 different cases reports, the 3-year survival rate was only of 7.36% and the median survival time of 10 months (1). Another analysis including 31 gastric HAC patients described that: i) 87% of them exhibited an increased secretion of AFP serum level; ii) 55% had a locoregional synchronous node extension; and iii) 25% had synchronous metastatic, especially hepatic. An overexpression of AFP was detected by immunohistochemistry (IHC) in 90.3% of cases (4). Conversely, Nagai et al showed that in 46% of HAC patients, any increase of AFP secretion was observed. Therefore, they proposed a novel description of HAC as an extrahepatic tumor with typical hepatocyte cells with or without AFP secretion (5). Importantly, HAC must not be confounded with classical gastric adenocarcinoma, which can be associated with AFP overexpression, and having a better prognosis. Indeed, gastric HAC prognosis is poorer than classical histological types ones (4,6). Currently, the treatment of metastatic HAC (mHAC) remains not elucidated. Herein, we report two case-reports of mHAC patients. Moreover, through a pertinent review of the literature, we aim to analyse the different current therapeutic approaches for mHAC.

Materials and methods

We have performed a PRISMA-compliant systematic review of literature concerning the use of chemotherapy in mHAC (7). Inclusion criteria for articles published from January 2001 to October 2016 were: i) mHAC; ii) treated by chemotherapy; and iii) with an evaluation of the response. The following term was used in the Pubmed and Science Direct database exploration: ‘metastatic hepatoid carcinoma’, or ‘hepatoid’ with mesh term ‘drug therapy’. We also performed an investigation in the Grey literature database and in all case reports published in open case reports journals, which are not indexed in Pubmed databases (Journal of Medical Case Report, BMJ Case Report, American Journal of Case Report, International Journal of Case Reports, Clinical Case Reports) with the following term, ‘hepatoid’. The flow chart respect PRISMA criteria, but no registration was carried out prospectively, explaining the lack of PROSPERO number (7). We identified 104 related reports in Pubmed Database and 9 in open case reports journals (Fig. 1). Though, no related article was found in Grey Literature. Thirty articles were not pertinent and 13 were not available in English full text. Sixty-eight full text articles were assessed for eligibility. Among them, 8 were not related to HAC, 10 exhibited no metastasis features and 24 were not associated with chemotherapy. The nature of chemotherapy was not described in 10 case reports from 5 articles. The response to chemotherapy was not related in 9 case reports from 3 articles. Finally, only 18 articles concerning 20 patients were included. The best overall response (BOR), corresponding to the addition of best metastatic response (BMR) and the best primitive lesion response (BPR) to chemotherapy was reported and assessed according to Response Evaluation Criteria In Solid Tumors (RECIST version 1.1). The decrease of serum AFP levels following the treatment, named ‘biological response’ (BioR), was also assessed.

Figure 1.

PRISMA-Compliant Flow chart of selection cases treated by chemotherapy in metastatic hepatoid adenocarcinoma: 1Grey literature and Open Case Report Journal not indexed in Pubmed. n, number of patients.

First case report

Mr. B., a 64-year-old French man, suffering from gastric reflux with hiatal hernia treated by proton inhibitor, was admitted to the gastroenterology department in February 2006 for epigastric and right hypochondrium pains associated with an anorexia and lose of weight. During the physical examination, the patient had a rapidly worsening general state with i) a Performans Status estimated to 4; ii) an icterus; iii) a paraneoplasic fever; and iv) a painful massive hepatomegaly. The laboratory investigation showed a biological chronic inflammation with LDH 25 times upper limit of normal (ULN), ASAT 2 ULN, and icteric cholestasis with total bilirubin at 120 µmol/l. Carcinoembryonic antigen (CEA) and CA 19-9 were normal, but serum AFP was elevated to 2,600 ng/ml. An oesogastroduodenoscopy discovered an ulcerated cardial tumoral lesion. Ultrasound scanning and computed tomography (CT) scans found three lesions in the right liver. A histopathologic examination of the cardia biopsy showed an ulcered HAC of the cardia, with tubulopapillary contingents. It was composed of large cells, with large nucleus, eosinophilic cytoplasm, and few hyaline balls. The periodic acid-Schiff (PAS) coloration, as well as the IHC of Hep Par antibodies, was negative. The histological examination of the hepatic biopsy showed the same HAC with the same cellular features, but with more necrosis aspects. The IHC study revealed CK19 positive (+), CK7 negative (−), CD10-, Chromogranine-, and Anti-synaptophysine negative cells.

A systemic chemotherapy was delivered associating cisplatin 25 mg/m2 with etoposide 100 mg/m2 each day, day 1 to day 3, every 3 weeks. After one cycle, an impressive clinical improvement was notified with a decrease of abdominal pains and an extinction of hepatomegaly, with a straight decrease of icteric cholestasis although the AFP level was enhanced to 6,900 ng/ml. After 3 cycles, CT scans showed a good partial response on the liver metastasis and on the cardia lesion, confirmed after 6 cycles with a reduction of more than 80% of the size of liver metastasis. Moreover, the serum AFP levels were normalized. The Positron Emission Tomography (PET), realised two months after the end of chemotherapy, showed a complete metabolic gastric response and the persistence of two lesions in the segment VIII. The oesogastroduodenoscopy revealed an inflammatory cardia with complete histopathologic responses. After a one-year follow-up, a radical surgery associating gastrectomy and right hepatotectomy was decided by pluridisciplinary committee, and carried out. The patient was still alive, in complete remission at the last CT scan, more than 9 years after his diagnosis (Tables I and II; case 1).

Table I.

Characteristics of metastatic HAC cases reported in literature.

Case	Year	First author	Nationality	Sex	Age	Primitive site	Metastasis site(s)	Synchrone metastasis	IHC AFP	Initial AFP[a]	CEA[a]	Initial surgery	(Refs.)
3	2002	Shimada	Japanese	F	71	Stomach	Liver	Yes	+	5190	NA	No	(9)
4	2002	Shimada	Japanese	M	63	Stomach	Liver	Yes	+	156	NA	No	(9)
5	2005	Chiba	Japanese	M	47	Stomach	Liver	No	–	606.8	ULN	Yes	(15)
6	2007	Takayema	Japanese	M	64	Stomach	Liver	Yes	+	1497.8	72.7	No	(10)
7	2009	Takahashi	Japanese	M	51	Stomach	Liver	Yes	+	91	NA	No	(11)
8	2009	Lin	Chinese	F	56	Stomach	Liver	Yes	+	9457	ULN	No	(16)
9	2009	Gálvez-Muñoz	European	M	75	Stomach	Liver/nodes	Yes	+	4500	460	Yes	(17)
10	2011	Mokrim	Moroccan	M	52	Lung	Lung/nodes	Yes	+	5000	NA	No	(27)
11	2012	Cappetta	European	F	75	Colon	Peritoneal/nodes	No	+	ULN	ULN	Yes	(18)
12	2013	Ye	Chinese	M	54	Stomach	Lung	No	+	99	ULN	Yes	(19)
13	2013	Ye	Chinese	F	61	Stomach	Spleen	Yes	+	>50000	ULN	No	(19)
14	2013	Ahn	Korean	M	68	Stomach	Liver	No	+	NA	NA	Yes	(20)
15	2013	Majumder	American	M	60	Pancreas	Liver	Yes	–	ULN	ULN	No	(21)
16	2014	Nagai	Japanese	M	62	Stomach	Liver	Yes	NA	NA	NA	Yes	(22)
17	2015	Chen	American	M	36	Colon	Peritoneal/nodes	No	+	4896	ULN	Yes	(23)
18	2015	Hu	Chinese	M	28	Mediastinum	Liver/lung	Yes	+	155000	NA	Yes	(24)
1	2017	Simmet[b]	European	M	64	Stomach	Liver	Yes	–	2600	ULN	No
2	2017	Simmet[b]	European	F	60	Stomach	Liver	Yes	–	76000	176	No

ng/ml

Present study. IHC, immunohistochemestry; AFP, α-fetoprotein; ULN, under limit of normal; NA, not available.

Table II.

Description of response to chemotherapy for metastatic HAC reported cases.

Case	Chemotherapy regimen	BOR	BPR	BMR	BioR	AFP nadir[a]	Surgery	Local surgery	Metastasis alive	OS
3	Cisplatin/paclitaxel	PR	PR	PR	Yes	155.9 (3.8)	Yes	No	No	14
4	Weekly paclitaxel	CR	Na	CR	Yes	700 (2)	No	No	Yes	8+
5	Cisplatin/Etoposide/5FU	CR	CR	CR	Yes	<10 (9)	Yes	No	Yes	106+
6	Doxorubicin/mitomycin/5FU	PR	CR	PR	Yes	<10 (945)	Yes	No	No	20
7	Cisplatin/capecitabine	SD	SD	SD	Yes	NA	No	No	Yes	8+
8	FOLFIRI (5FU+ irinotecan) bevacizumab	PD	Na	PD	Na	NA	No	No	No	3
9	Sorafenib	SD	SD	SD	Na	NA	No	No	No	8
10	Paclitaxel/capecitabine	PD	Na	PD	No	8431	No	No	No	13
11	FOLFOX (5FU+ oxaliplatin)	PD	PD	PD	No	>50000	No	No	No	8
12	Cisplatin/capecitabine	PD	Na	PD	Na	NA	No	No	No	15
13	Gemcitabine	PD	PD	PD	Na	NA	No	No	No	3
14	Cisplatin/S1	PR	Na	PR	Na	NA	No	No	Yes	24+
15	FOLFOX (5fu+oxaliplatin)/bevacizumab	SD	Na	SD	Yes	260 (18)	No	No	Yes	6+
16	Carboplatin/paclitaxel/Sorafenib	PR	PR	PR	Yes	25 (7)	No	No	No	11
1	Cisplatin/Etoposide	PR	CR	PR	Yes	<10 (260)	Yes	Yes	Yes	120+
2	Cisplatin/Etoposide	PR	CR	PR	Yes	1751 (43)	No	No	No	17

Division coefficient between initial AFP level and the nadir. BOR, best overall response; BPR, best primitive response; BMR, best metastatic response; BioR, biological response; AFP, α-fetoprotein; OS, overall survival; RC, complete response; RP, partial response; SD, stability disease; PD, progression disease; +, censured data.

Second case report

A 60 year-old French woman was admitted to the emergency ward in December 2014 for insomnia-related pains in her right hypochondrias, associated with anorexia, asthenia and a lose of weight of 3 kg in one month. Gastro-duodenal ulcer was notified in her digestive antecedents. The physical examination found a hepatomegaly and epigastric pains on the palpation. The laboratory investigation found ASAT 2 ULN, LDH to 7 ULN, and a non-icteric cholestasis. CT scans showed a tumor in the cardia extended to the low-oesophagus and greater curvature, numerous liver metastasis, up to 7 cm, with hypervascularization and necrotic center in arterial phase. In Magnetic Resonance Imaging (MRI), cardia tumor and hepatic metastasis appeared hyper-intense in T2 and diffusion sequence, with peripheral arterial enhancement (ring-shape) without washout. PET revealed an intense hypermetabolism of the liver metastasis and primary lesion (Fig. 2). With particularly features in CT scans, tumoral markers have been analysed: 76,000 ng/ml for AFP, 176 IU/ml for CEA, and normal CA19-9. Oesogastroduodenoscopy showed an infiltrated ulceration of 4 cm on low-oesophagus and cardia on the third of the curvature. The histopathologic examination confirmed a HAC: round cells with big nuclei not much nucleolated, occasionally associated with a very dense chromatin, an eosinophile cytoplasm, but without intracytoplasmic hyaline globules as evaluated by PAS. As revealed by IHC studies, tumors were found KL1 positive (+), Glypican+, Glutamine Synthetase+, CK5-6 low, Hep Par antibodies low, CK20 negative (−), CK5-, AFP negative, Betacatenine-, Synaptophysin-, and P63 or Oestrogen receptors negative.

Figure 2.

Second patient. Evaluation of the response to positron emission tomography (A) before and (B) after 3 cisplatin etoposide cycles.

A systemic chemotherapy was delivered associating cisplatin 25 mg/m2 with etoposide 100 mg/m2 each day, day 1 to day 3, every 3 weeks, with a rapid decrease of pain, after the first cycle, although an initial increase of tumoral markers was observed (Fig. 3). The first evaluation after 3 cycles by PET showed a metabolic complete response on the primary oesogastric lesion and metabolic partial response on the metastatic liver lesions (Fig. 2). After 6 cycles, persistence of complete response was confirmed on the primary lesion, but an increase in size and intensity of liver metastasis was observed. A maintenance therapy by oral etoposid was administrated, but stopped 3 months later due to marker's increase. Nowadays, PET scan confirmed a hepatic progression with appearance of hypermetabolism on the left lower paratracheal nodes, without any relapse in oesogastric junction. A second line treatment with carboplatin and etoposid was carried out leading to a novel decrease of AFP levels before observing any progression (Fig. 3). Finally, a third treatment by XELIRI (capecitabin and irinotecan) was administrated, without any efficiency. The patient died after 23 months-follow-ups (Tables I and II; case 2).

Figure 3.

Second Patient. Evaluation of α-fetoprotein level, before and after chemotherapy. AFP, α-fetoprotein; EP, etoposide + cisplatin; CE, carboplatin + etoposide; XELIRI, irinotecan + capecitabin.

Results

Only one retrospective Korea cohort of 13 mHAC was found in our study with: i) one partial response reported with 5-fluoruracil (5-FU) associated with cisplatin; and ii) a second one with cisplatin-paclitaxel in second line (8). Nevertheless, the others patients received different chemotherapy regimens. Therefore, as the nature of the treatment for each patients remained unknown, this cohort was excluded for the final analysis. Moreover, we have reported 2 colon, 2 lung, 2 pancreas, 1 bladder, 1 peritoneal, 1 mediastinum mHACs and 11 gastric mHACs (Tables I and III, especially with sorafenib treatment). Including our two case reports, the median age of the diagnosis was 56 years. Patients (73%) were male, 63% (14/22) and 72% (16/22) exhibited liver metastasis and synchrone metastasis, respectively. IHC AFP study was positive in 75% of cases (15/20). When increased, the average AFP serum level was of 16,597 ng/ml. An initial surgery was carried out in 41% of cases (9/22). 11/22 BOR were observed with chemotherapy. Among them, 8/22 were partial responses and 3/22 complete ones. The complete response concerned 3 Japanese male patients with gastric HAC and liver metastasis. 55% (12/22) of the patients received a cisplatin-based regimen, whose 9/12 had partial or complete responses. Among partial or complete response of all case reports, 9/11 (81%) had a cisplatin-based chemotherapy. One another partial response was observed with a triple combined therapy: mitomycin-C, doxorubicin and 5-fluorouracil (Table II; case 8).

Table III.

Characteristic and response to sorafenib for metastatic HAC reported cases.

Case	Year	First author	Nationality	Sex	Age	Primitive site	Metastasis site(s)	IHC AFP	Initial AFP[a]	Chemotherapy regimen	BOR	BioR	AFP nadir[b]	Alive	OS	(Refs.)
19	2010	Metzgeroth	European	M	21	Peritoneal	Peritoneal	–	ULN	Sorafenib	SD	NA	NA	No	6	(14)
20	2011	Karayiannakis	European	F	60	Bladder	Nodes	+	62	Sorafenib	SD	Yes	<10 (6)	No	20	(25)
21	2012	Petrelli	European	M	37	Pancreas	Liver lung nodes	NA	11	Sorafenib	SD	NA	NA	No	8	(26)
22	2015	Gavrancic	American	M	64	Lung	Bones nodes	+	181	Carboplatin/paclitaxel/sorafenib	PR	Yes	25 (7)	No	11	(12)

ng/ml

Division coefficient between initial AFP level and the nadir. IHC, immunohistochemistry; AFP, α-fetoprotein; BOR, best overall response; BioR, biological response; OS, overall survival; ULN, under limit of normal; PR, partial response; SD, stability disease; NA, not available.

Three patients were still alive with a follow-up superior to one year; these 3 patients were under Cisplatin-based chemotherapy regimen (Table II; cases 1, 7 and 14). Finally, BioR was observed in 14 of 16 evaluable patients and AFP serum levels were normalized in 4 of 15 included patients of our review (Table II; cases 1, 4, 7 and 8).

In addition, 4 patients were treated by sorafenib in literature (Table III). One of them, presenting a lung mHAC, also received an additional lung-chemotherapy regimen (Table III; case 22) (12). Three other patients were treated in monotherapy, which permitted a greater stability of the disease (Table III; cases 19, 20 and 21).

Discussion

Based on our investigation, we assume to describe the first two case reports of mHAC treated by cisplatin-etoposid as first-line chemotherapy leading to major partial and complete responses considering the primitive lesion. Indeed, we report a complete biological response: after a nine-year follow-up, we consider the patient to be completely treated from mHAC (described as the first case report). The treatment efficiency seems to be mostly due to cisplatin as we could detect a recurrence on the liver metastasis under oral etoposid in the case 2. As the maximal dose of administrated cisplatin had to be taken into account, this was preventing an additional cisplatin regimen in case 2. As described in case 2, other chemotherapy regimens appeared as inefficient as second and third lines treatment.

The review of literature is very limited and very few articles concerning the treatment of mHACs were reported. Lots of articles had to be excluded because no data regarding neither the kind of used chemotherapy nor its response were described. Therefore, these results had to be carefully interpreted and analysed. Indeed, as it is only an analysis of retrospective cases report, we cannot avoid some publication bias. In addition, the dose and schedules of chemotherapy administration were often not described in literature. Our results revealed a partial or complete response in 11 cases reports whom 81% had a Cisplatin-based regimen. Only one case, treated by cisplatin-etoposide-5-FU, can be identified as an efficient treatment with a long follow-up.

In our sense, cisplatin is probably the most interesting regimen to treat mHACs. These results were strongly correlated with ex vivo studies. Indeed, in a xenograft model of AFP-producing gastric cancer, mitomycin-C and cisplatin treatments might be effective to induce suppression of tumor growth, whereas 5-FU, doxorubicin, and epirubicin were shown as inefficient (13). In our review, two complete responses have been observed with a cisplatin-based regimen or mitomycin-C regimen. Other usual chemotherapies carried out in digestive cancer as irinotecan, oxaliplatin, gemcitabine or 5-FU, are appearing as inefficient in mHAC (Table II; cases 11, 13, 15 and 17).

Concerning targeted therapies, we do not possess full information. We can suppose that sorafenib which is the reference treatment in non-operable hepatocellular carcinoma could be a treatment option in HAC since they have similar histological features. An interesting progression free survival was reported in our review (Table III). In addition, an analysis of peritoneal mHAC in a 21-year-old man, showed a strong activation of the epidermal growth factor, and of the kinases ERK1 and AKT1 (14). Performing genome sequencing could be interesting in order to understand the molecular biology underlying mHAC (not described in the present time). In our cases, histopathological material was old or little biopsy materials, which is a strong limit to carry out a next sequencing generation.

Concerning non-gastric mHAC, we have stated only 2/7 partial responses in a lung and mediastinum primitive, and no objective responses in the two cases of colorectal HACs treated by a combined therapy composed of FOLFOX (oxaliplatin and 5-FU) plus bevacizumab, or FOLFIRI (irinotecan and 5-FU) plus bevacizumab (Table II; cases 11 and 17, respectively). No objective responses were related in a pancreatic HAC treated by gemcitabine. Consequently, traditional regimens seem to be not efficiency in mHAC. Cisplatin-based regimen seems to be the best option in non-gastric primitive HAC. Moreover radical surgery of primitive lesion or residual lesion could be ever considered and discussed again in case of good and durable response in mHACs as reported in the case 1.

In conclusion, HAC represents a very rare and aggressive subtype of cancer defined as extrahepatic tumor with hepatocyte differentiation and potentially an increased AFP secretion. Currently, the treatment of mHAC remains not elucidated. We reported two cases of patients with mHAC successfully treated by chemotherapy with cisplatin and etoposide as first line leading to complete response. One of them is still alive after more than 9 years. In the absence of prospective trials in this rare cancer, we assume that cisplatin-based chemotherapy regimen could be the best first-line treatment in mHAC and considering as well our real-life experience as in view of literature, with 81% of response. Since the data of genome-wide analysis in cancers, it might be useful to provide some information with next generation sequencing in HAC, in order to find efficient target therapies.